ClinicalTrials.gg
CompletedNCT06502379Updated Dec 11, 2025

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

A Phase 1 interventional study of AZD8965 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
57th of 188
147 · median 61
Started
2024
with 11 others
Phase 1
39 of 236
3 open now
Registered
210th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 57th largest by enrollment of the 188 interventional ones that give a count, is one of 12 that started in 2024, is one of 39 in phase 1, and was the 210th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.

Read the detailed description

This is a first in human single and multiple ascending dose study. The study consists of 4 parts: Part 1 (single ascending dose [SAD]), Part 2 (multiple ascending dose [MAD]), Part 3A (Japanese and Chinese SAD), Part 3B (Japanese and Chinese combined SAD and MAD), and Part 4 (Food Effect).

Each study part includes a 28-day screening period and a residential period during which participants will be resident at the Clinical Unit from the day before study intervention administration (Day -1) until at least 48-72 hours after the study intervention administration.

03

Conditions studied

  • Healthy Participants

Keywords

  • Idiopathic Pulmonary Fibrosis
  • Lung disease
  • Pharmacokinetics
  • Food Effect
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants (including Japanese and Chinese participants) with suitable veins for cannulation or repeated venipuncture.
  • All females of must have a negative pregnancy test at the Screening Visit (serum) and on admission (urine) to the Clinical Unit.
  • All females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective with low user dependency and their non-sterilized male partners must use a condom, to avoid pregnancy from the time of first administration of study intervention until 20 days after the last dose of study intervention. Females must not use hormonal contraceptives or hormone replacement therapy during the study.
  • Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and without an alternative medical cause and the follicle stimulating hormone (FSH) level is in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not acceptable.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the specified contraception methods from the time of first administration of study intervention administration until 20 days after the last dose of study intervention.
  • Have a (BMI) between 18 and 30 kilogram (kg)/square meter (m2) inclusive and weigh at least 45 kg.

Part 3A and Part 3B (Japanese Participants)

  • Healthy Japanese participants are eligible based on meeting all of the following:

    1. Born in Japan
    2. Have 2 Japanese biological parents and 4 Japanese grandparents.
    3. Did not live outside Japan for more than 10 years at the time of Screening. Part 3A and Part 3B (Chinese Participants)
  • Healthy Chinese participants. Participants of Chinese ancestry are eligible based on meeting all of the following:

    1. Born in mainland China, Hong Kong, Macau, or Taiwan
    2. Have 2 Chinese biological parents and 4 Chinese grandparents as confirmed by the interview.
    3. Did not live outside China for more than 10 years at the time of Screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk or influence the results or the participant's ability to participate in the study.
  • Chronic or ongoing gastrointestinal, respiratory, hepatic, renal disease, pancreatic disease, diabetes mellitus, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Chronic or ongoing neurological disorder, any clinically important past or ongoing psychiatric disorder which may confound assessment of the potential neurologic effects of this product.
  • Participants with a history of hypertension or cardiovascular disease.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Participant with chronic infections (e.g., urinary tract infection) or who are at increased risk of infection (e.g., surgery, trauma, severe dental disease, or significant infection).
  • Participants with a known or suspected defect in the function of the urea cycle, or with family history of a urea cycle disorder in one or more biological relative.
  • Any abnormal laboratory values and vital signs.
  • Ongoing acquired or inherited immunodeficiency disorders, including but not limited to (HIV) or common variable immunodeficiency, or the participant is taking immune replacement therapy.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8965.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Part 1: SAD Cohort 1 - AZD8965 (Dose 1)

    Participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 1: SAD Cohort 2 - AZD8965 (Dose 2)

    Participants will receive a single dose of AZD8965 (Dose 2) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 1: SAD Cohort 3 - AZD8965 (Dose 3)

    Participants will receive a single dose of AZD8965 (Dose 3) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 1: SAD Cohort 4 - AZD8965 (Dose 4)

    Participants will receive a single dose of AZD8965 (Dose 4) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 1: SAD Cohort 5 - AZD8965 (Dose 5)

    Participants will receive a single dose of AZD8965 (Dose 5) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 2: MAD Cohort 1 - AZD8965 (Dose 1)

    Participants will receive multiple doses of AZD8965 (Dose 1) or matching placebo to AZD8965 from Day 1 to Day 8.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 2: MAD Cohort 2 - AZD8965 (Dose 2)

    Participants will receive multiple doses of AZD8965 (Dose 2) or matching placebo to AZD8965 from Day 1 to Day 8.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 2: MAD Cohort 3 - AZD8965 (Dose 3)

    Participants will receive multiple doses of AZD8965 (Dose 3) or matching placebo to AZD8965 from Day 1 to Day 8.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 3A: SAD Cohort 1 (Japanese) - AZD8965 (Dose 1)

    Japanese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 3A: SAD Cohort 2 (Japanese) - AZD8965 (Dose 2)

    Japanese participants will receive a single dose of AZD8965 (Dose 2) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 3A: SAD Cohort 3 (Chinese) - AZD8965 (Dose 1)

    Chinese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 3B: Single and multiple ascending dose (SMAD) Cohort 1 (Japanese) - AZD8965 (Dose 1)

    Japanese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1, followed by multiple doses of AZD8965 or matching placebo from Day 3 until Day 9.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 3B: SMAD Cohort 2 (Chinese) - AZD8965 (Dose 1)

    Chinese participants will receive a single dose of AZD8965 (Dose 1) or matching placebo to AZD8965 on Day 1, followed by multiple doses of AZD8965 or matching placebo from Day 3 until Day 9.

    Drug: AZD8965 · Other: Placebo

  • Experimental
    Part 4: Food Effect Cohort - AZD8965

    Participants will receive 2 single dose treatments of AZD8965 \[following an overnight fast of at least 10 hours in a fasted state or a fed state (after a high fat meal)\].

    Drug: AZD8965

Interventions

  • DrugAZD8965

    AZD8965 will be administered orally.

  • OtherPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Parts 1 and 3A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD8965 following oral administration of single ascending doses to healthy participants.

    Time frame: SAEs: From Screening (Day -28) to 5 weeks; AEs: From Day 1 to 5 weeks

  2. Parts 2 and 3B: Number of participants with AEs and SAEs

    To assess the safety and tolerability of AZD8965 following oral administration of multiple ascending doses to healthy participants.

    Time frame: SAEs: From Screening (Day -28) to 8 weeks; AEs: From Day 1 to 8 weeks.

  3. Part 4: Maximum observed drug concentration (Cmax)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  4. Part 4: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  5. Part 4: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  6. Part 4: Time to reach maximum observed concentration (tmax)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  7. Part 4: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  8. Part 4: Terminal elimination half-life (t½λz)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  9. Part 4: Mean Residence Time (MRTinf)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  10. Part 4: Apparent total body clearance (CL/F)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  11. Part 4: Apparent volume of distribution based on the terminal (Vz/F)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  12. Part 4: Accumulation ratio for AUC (Rac AUC)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  13. Part 4: Accumulation ratio for Cmax (Rac Cmax)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  14. Part 4: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 5

  15. Part 4: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 5

  16. Part 4: Relative bioavailability calculated as test AUC/reference AUC (Frel AUC)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  17. Part 4: Relative bioavailability calculated as test Cmax/reference Cmax (Frel Cmax)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)

  18. Part 4: Renal clearance (CLR)

    To assess the effect of a high fat meal compared to fasting conditions on the PK of active drug and pro-drug following oral administration of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 5

Secondary outcomes

  1. Parts 1, 2, 3A and 3B: Maximum observed drug concentration (Cmax)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  2. Parts 1, 2, 3A and 3B: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  3. Parts 1, 2, 3A and 3B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  4. Parts 1, 2, 3A and 3B: Time to reach maximum observed concentration (tmax)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  5. Parts 1, 2, 3A and 3B: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  6. Parts 1, 2, 3A and 3B: Terminal elimination half-life (t½λz)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  7. Parts 1, 2, 3A and 3B: Mean Residence Time (MRTinf)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  8. Parts 1, 2, 3A and 3B: Apparent total body clearance (CL/F)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  9. Parts 1, 2, 3A and 3B: Apparent volume of distribution based on the terminal (Vz/F)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  10. Parts 1, 2, 3A and 3B: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9

  11. Parts 1, 2, 3A and 3B: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9

  12. Parts 1, 2, 3A and 3B: Renal clearance (CLR)

    To characterize the PK of active drug and pro-drug following oral administration of single and multiple ascending doses of AZD8965 in healthy participants.

    Time frame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9

  13. Parts 2 and 3B: Area under concentration-time curve in the dosing interval (AUCtau)

    To characterize the PK of active drug and pro-drug following oral administration of multiple ascending doses of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  14. Parts 2 and 3B: Accumulation ratio for AUC (Rac AUC)

    To characterize the PK of active drug and pro-drug following oral administration of multiple ascending doses of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  15. Parts 2 and 3B: Accumulation ratio for Cmax (Rac Cmax)

    To characterize the PK of active drug and pro-drug following oral administration of multiple ascending doses of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  16. Parts 2 and 3B: Temporal Change Parameter (TCP)

    To characterize the PK of active drug and pro-drug following oral administration of multiple ascending doses of AZD8965 in healthy participants.

    Time frame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)

  17. Part 4: Number of participants with AEs and SAEs

    To assess the safety and tolerability of AZD8965 under fasted and fed (after intake of a high fat meal) conditions in healthy participants.

    Time frame: SAEs: From Screening (Day -28) to 6 weeks; AEs: From Day 1 to 6 weeks

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2025, 9 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is close to that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 16, 2024
StartActual
Aug 2, 2024
Primary completionActual
Jun 1, 2025
CompletionActual
Nov 15, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06502379
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Aug 2, 2024
Primary completion
Jun 1, 2025
Completion
Nov 15, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion